ImmunityBio, Inc. entered into a $30 million promissory note with Nant Capital, LLC for non-convertible debt financing, and held its Annual Meeting of Stockholders where directors were re-elected and the appointment of Ernst & Young LLP as the independent registered public accounting firm was ratified.